Physician profile
Pedro Hernandez
NPI 1649498569
$3,451.30
in general payments reported to CMS, 2019-2025
27 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $903 · 2021: $436 · 2022: $394 · 2023: $212 · 2024: $497 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.60 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $770.72 | 2019-2025 | Jynarque |
| Astrazeneca Uk Limited | $633.67 | 2020 | |
| Aurinia Pharma U.S., INC. | $400.46 | 2022-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $355.02 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $259.59 | 2021-2025 | Acthar |
| Calliditas Therapeutics US INC. | $154.30 | 2022-2025 | Tarpeyo |
| Amgen INC. | $154.03 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $114.76 | 2021-2022 | |
| Akebia Therapeutics INC | $102.33 | 2024-2025 | Vafseo |
| Novo Nordisk INC | $81.23 | 2025 | Ozempic |
| Travere Therapeutics, INC. | $70.06 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.47 | 2025 | Jardiance |
| Baxter Healthcare | $40.87 | 2021-2024 | Seprafilm |
| Vifor Pharma, INC. | $40.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.62 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $33.87 | 2025 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $30.69 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.69 | 2024 | |
| Vapotherm INC | $24.92 | 2021 | |
| Ardelyx, INC. | $23.00 | 2024 | Ibsrela |
| Lilly USA, LLC | $17.78 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $15.61 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.